CN101952241B - 治疗维生素b12缺乏的方法 - Google Patents

治疗维生素b12缺乏的方法 Download PDF

Info

Publication number
CN101952241B
CN101952241B CN200880119724.0A CN200880119724A CN101952241B CN 101952241 B CN101952241 B CN 101952241B CN 200880119724 A CN200880119724 A CN 200880119724A CN 101952241 B CN101952241 B CN 101952241B
Authority
CN
China
Prior art keywords
vitamin
pharmaceutical composition
snac
tablet
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880119724.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN101952241A (zh
Inventor
C·卡斯特里
L·克拉吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Emisphere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101952241(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Technologies Inc filed Critical Emisphere Technologies Inc
Publication of CN101952241A publication Critical patent/CN101952241A/zh
Application granted granted Critical
Publication of CN101952241B publication Critical patent/CN101952241B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200880119724.0A 2007-11-02 2008-10-31 治疗维生素b12缺乏的方法 Expired - Fee Related CN101952241B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US98489807P 2007-11-02 2007-11-02
US60/984,898 2007-11-02
US2010808P 2008-01-09 2008-01-09
US61/020,108 2008-01-09
US8356608P 2008-07-25 2008-07-25
US61/083,566 2008-07-25
PCT/US2008/082064 WO2009059188A1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency

Publications (2)

Publication Number Publication Date
CN101952241A CN101952241A (zh) 2011-01-19
CN101952241B true CN101952241B (zh) 2014-06-11

Family

ID=40591491

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880119724.0A Expired - Fee Related CN101952241B (zh) 2007-11-02 2008-10-31 治疗维生素b12缺乏的方法

Country Status (18)

Country Link
US (3) US8022048B2 (enExample)
EP (1) EP2215047B1 (enExample)
JP (1) JP5555634B2 (enExample)
KR (1) KR101344369B1 (enExample)
CN (1) CN101952241B (enExample)
AU (1) AU2008318423B2 (enExample)
BR (1) BRPI0817396C8 (enExample)
CA (1) CA2704780C (enExample)
CL (1) CL2010000434A1 (enExample)
CO (1) CO6280475A2 (enExample)
DK (1) DK2215047T3 (enExample)
ES (1) ES2443817T3 (enExample)
MX (1) MX2010004716A (enExample)
NZ (1) NZ585080A (enExample)
PL (1) PL2215047T3 (enExample)
PT (1) PT2215047E (enExample)
RU (1) RU2469728C2 (enExample)
WO (1) WO2009059188A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017346A2 (en) * 2009-08-03 2011-02-10 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
TWI590829B (zh) * 2010-02-24 2017-07-11 艾米斯菲爾科技股份有限公司 口服ｂ１２的療法
RS60321B1 (sr) 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
US8805208B2 (en) * 2012-02-03 2014-08-12 Tyco Electronics Subsea Communications Llc System and method for polarization de-multiplexing in a coherent optical receiver
PL2827885T3 (pl) 2012-03-22 2019-01-31 Novo Nordisk A/S Kompozycje peptydów GLP-1 i ich otrzymywanie
RS58636B1 (sr) 2012-03-22 2019-05-31 Novo Nordisk As Kompozicije koje sadrže sredstvo za isporuku i njihova priprema
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6983868B2 (ja) 2016-04-22 2021-12-17 レセプター・ホールディングス・インコーポレイテッド 即効性の植物由来医薬化合物及び栄養補給剤
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
WO2019071211A1 (en) * 2017-10-05 2019-04-11 Receptor Life Sciences, Inc. HERB COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY
KR20200065009A (ko) * 2017-10-05 2020-06-08 리셉터 홀딩스, 인크. 신속 개시 및 연장된 작용 식물계 및 합성 칸나비노이드 제형
CN111683676B (zh) 2018-02-02 2024-06-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
AU2019385420A1 (en) 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050186267A1 (en) * 2002-09-13 2005-08-25 Thompson Diane O. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2266412A1 (en) * 1996-09-18 1998-03-26 William J. Sarill Compositions containing cobalamin and amino acids
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DK1128835T3 (da) * 1998-12-28 2006-10-23 Cobalis Corp Cyanocobalamin (vitamin 12)-behandling ved allergisk sygdom
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
EP1284724B1 (en) 2000-03-21 2012-04-18 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
ES2282436T3 (es) 2001-06-01 2007-10-16 Novartis Ag Administracion oral de hormona paratiroide y calcitonina.
BRPI0211932B1 (pt) 2001-08-17 2016-12-06 Novartis Ag composição farmacêutica na forma de dosagem sólida para liberação oral, e uso de sal dissódio de ácido n-(5-cloro-saliciloil)-8-aminocaprílico (5-cnac)
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
TWI307279B (en) 2002-08-01 2009-03-11 Novartis Ag Oral administration of calcitonin
CN100579955C (zh) 2003-04-04 2010-01-13 帝斯曼知识产权资产管理有限公司 N-烷氧基草酰丙氨酸酯的制备方法
US6938439B2 (en) 2003-05-22 2005-09-06 Cool Clean Technologies, Inc. System for use of land fills and recyclable materials
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
EP1643978A1 (en) 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
DE602004023093D1 (de) 2003-07-11 2009-10-22 Novartis Ag N mit einem abgabemittel in mikronisierter form
BRPI0412265A (pt) 2003-07-23 2006-09-05 Novartis Ag uso de calcitonina em osteoartrite
CN102040537A (zh) * 2004-05-06 2011-05-04 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
US20060024241A1 (en) * 2004-08-02 2006-02-02 Bebaas, Inc. Vitamin B12 compositions
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
CN101296694A (zh) 2005-11-04 2008-10-29 真塔公司 药物镓组合物和方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050186267A1 (en) * 2002-09-13 2005-08-25 Thompson Diane O. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Oral Delivery of Insulin with the eligen Technology:Mechanistic Studies;Dmitry Malkov et al;《Current Drug Delivery》;20051231;第2卷(第2期);第191-197页 *

Also Published As

Publication number Publication date
US8022048B2 (en) 2011-09-20
NZ585080A (en) 2012-05-25
CA2704780A1 (en) 2009-05-07
US20130040910A1 (en) 2013-02-14
RU2469728C2 (ru) 2012-12-20
JP2011502997A (ja) 2011-01-27
KR20100126263A (ko) 2010-12-01
JP5555634B2 (ja) 2014-07-23
CL2010000434A1 (es) 2011-01-28
EP2215047B1 (en) 2013-11-20
CO6280475A2 (es) 2011-05-20
EP2215047A4 (en) 2010-11-10
AU2008318423B2 (en) 2013-12-05
BRPI0817396A2 (pt) 2015-04-07
KR101344369B1 (ko) 2013-12-24
BRPI0817396C1 (pt) 2020-11-17
MX2010004716A (es) 2010-12-17
US20100016255A1 (en) 2010-01-21
BRPI0817396B8 (pt) 2020-02-04
AU2008318423A1 (en) 2009-05-07
EP2215047A1 (en) 2010-08-11
CA2704780C (en) 2014-06-10
PT2215047E (pt) 2014-01-20
US8288360B2 (en) 2012-10-16
DK2215047T3 (da) 2014-02-03
CN101952241A (zh) 2011-01-19
WO2009059188A1 (en) 2009-05-07
PL2215047T3 (pl) 2014-05-30
HK1146480A1 (en) 2011-06-10
BRPI0817396C8 (pt) 2021-05-25
US8557792B2 (en) 2013-10-15
US20110293589A1 (en) 2011-12-01
RU2010118423A (ru) 2011-12-10
ES2443817T3 (es) 2014-02-20
BRPI0817396B1 (pt) 2019-04-24

Similar Documents

Publication Publication Date Title
CN101952241B (zh) 治疗维生素b12缺乏的方法
WO1996014852A1 (en) Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna)
JP2019001787A (ja) 抗炎症性の置換シクロブテンジオン化合物のコリン塩
US12257238B2 (en) Magnesium biotinate compositions and methods of use
US20200206247A1 (en) Oral b12 therapy
CN118370728A (zh) 一种glp-1ra载药纳米颗粒和制剂及其制备方法
CN103889420A (zh) 新盐及医药用途
CN116648243A (zh) 三苯基钙敏感化合物的制剂
RU2240784C1 (ru) Лекарственное средство на основе арбидола
JP2000264839A (ja) 結腸領域で高まった疼痛感応性と関連する機能障害及び／又は下行腸管の疾患の治療及び／又は予防のための医薬調剤並びにその製造法
HK1146480B (en) Method of treating vitamin b12 deficiency
CN118019525A (zh) Fxr激动剂的药物组合物及其制备方法
HK1225609B (en) Oral b12 therapy
EP3685831A1 (en) Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140611